1. Home
  2. NTLA vs CGBD Comparison

NTLA vs CGBD Comparison

Compare NTLA & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$10.75

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$12.67

Market Cap

906.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
CGBD
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
986.9M
906.2M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
NTLA
CGBD
Price
$10.75
$12.67
Analyst Decision
Buy
Hold
Analyst Count
22
7
Target Price
$19.83
$13.70
AVG Volume (30 Days)
3.6M
538.6K
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
13.03%
EPS Growth
N/A
N/A
EPS
N/A
1.14
Revenue
$57,528,000.00
$245,008,000.00
Revenue This Year
$1.96
$13.53
Revenue Next Year
N/A
$4.24
P/E Ratio
N/A
$11.13
Revenue Growth
33.52
2.55
52 Week Low
$5.90
$11.55
52 Week High
$28.25
$18.64

Technical Indicators

Market Signals
Indicator
NTLA
CGBD
Relative Strength Index (RSI) 61.75 51.59
Support Level $8.94 $12.25
Resistance Level $9.62 $12.78
Average True Range (ATR) 0.46 0.25
MACD 0.28 -0.02
Stochastic Oscillator 89.42 62.77

Price Performance

Historical Comparison
NTLA
CGBD

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: